Enzo Biochem (ENZ) 10-Q 9 Mar 16 2016 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jan. 31, 2016	Mar. 02, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	ENZO BIOCHEM INC
Document Type	10-Q
Current Fiscal Year End Date	--07-31
Entity Common Stock, Shares Outstanding		46,093,000
Amendment Flag	false
Entity Central Index Key	316,253
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jan. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jan. 31, 2016	Jul. 31, 2015
Current assets:
Cash and cash equivalents	$ 37,016	$ 18,109
Accounts receivable, net of allowances	12,877	12,109
Other receivables		6,650
Inventories	7,395	7,396
Prepaid expenses and other	1,866	2,222
Total current assets	59,154	46,486
Property, plant and equipment, net	8,730	7,948
Goodwill	7,452	7,452
Intangible assets, net	5,221	6,155
Other assets	349	353
Total assets	80,906	68,394
Current liabilities:
Loan payable	3,013	3,013
Accounts payable – trade	9,459	8,762
Accrued liabilities	9,556	11,297
Other current liabilities	2,476	886
Total current liabilities	24,504	23,958
Deferred taxes	30	37
Other liabilities	1,925	1,793
Total liabilities	$ 26,459	$ 25,788
Commitments and contingencies
Stockholders’ equity:
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 46,092,518 at January 31, 2016 and 46,062,065 at July 31, 2015	$ 461	$ 461
Additional paid-in capital	325,253	324,966
Accumulated deficit	(273,416)	(284,682)
Accumulated other comprehensive income	2,149	1,861
Total stockholders’ equity	54,447	42,606
Total liabilities and stockholders’ equity	$ 80,906	$ 68,394

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Jan. 31, 2016	Jul. 31, 2015
Preferred Stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred Stock, shares authorized	25,000,000	25,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common Stock, shares authorized	75,000,000	75,000,000
Common Stock, shares issued	46,092,518	46,062,065
Common Stock, shares outstanding	46,092,518	46,062,065

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2016	Jan. 31, 2015
Revenues:
Clinical laboratory services	$ 17,523	$ 14,725	$ 34,613	$ 30,547
Product revenues	6,578	7,723	14,265	15,725
Royalty and license fee income	459	644	859	1,644
Total revenues	24,560	23,092	49,737	47,916
Operating expenses:
Cost of clinical laboratory services	10,535	9,246	20,867	19,376
Cost of product revenues	3,206	3,818	6,817	7,513
Research and development	861	834	1,728	1,625
Selling, general, and administrative	11,280	9,670	21,505	19,955
Provision for uncollectible accounts receivable	459	601	1,163	1,142
Legal fee expense	2,411	2,804	4,012	5,270
Legal settlements, net	(11,650)		(18,450)
Total operating expenses	17,102	26,973	37,642	54,881
Operating Income (loss)	7,458	(3,881)	12,095	(6,965)
Other income (expense):
Interest	(42)	(49)	(82)	(118)
Other	11	(17)	65	2
Foreign exchange loss	(388)	(259)	(518)	(731)
Income (loss) before income taxes	7,039	(4,206)	11,560	(7,812)
(Provision) benefit for income taxes	(207)	115	(294)	(8)
Net income (loss)	$ 6,832	$ (4,091)	$ 11,266	$ (7,820)
Net income (loss) per common share:
Basic (in Dollars per share)	$ 0.15	$ (0.09)	$ 0.24	$ (0.17)
Diluted (in Dollars per share)	$ 0.15	$ (0.09)	$ 0.24	$ (0.17)
Weighted average common shares outstanding:
Basic (in Shares)	46,077	45,000	46,070	44,782
Diluted (in Shares)	46,518	45,000	46,353	44,782

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2016	Jan. 31, 2015
Net income (loss)	$ 6,832	$ (4,091)	$ 11,266	$ (7,820)
Other comprehensive income (loss):
Foreign currency translation adjustments	226	35	288	143
Comprehensive income (loss)	$ 7,058	$ (4,056)	$ 11,554	$ (7,677)

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 6 months ended Jan. 31, 2016 - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Jul. 31, 2015	$ 461	$ 324,966	$ (284,682)	$ 1,861	$ 42,606
Balance (in Shares) at Jul. 31, 2015	46,062,065
Net income for the period ended January 31, 2016			11,266		11,266
Vesting of restricted stock (in Shares)	6,751
Exercise of stock options		66			$ 66
Exercise of stock options (in Shares)	23,702				23,702
Share-based compensation charges		221			$ 221
Foreign currency translation adjustments				288	288
Balance at Jan. 31, 2016	$ 461	$ 325,253	$ (273,416)	$ 2,149	$ 54,447
Balance (in Shares) at Jan. 31, 2016	46,092,518

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2016	Jan. 31, 2015
Cash flows from operating activities:
Net income (loss)	$ 11,266	$ (7,820)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization of property, plant and equipment	1,059	1,014
Amortization of intangible assets	843	859
Provision for uncollectible accounts receivable	1,163	1,142
Deferred income tax benefit	(5)	(48)
Share-based compensation charges	221	203
Accrual for share-based 401(k) employer match expense	439	296
Foreign exchange loss	333	570
Changes in operating assets and liabilities:
Accounts receivable	(1,952)	(524)
Other receivables	6,650
Inventories	(20)	306
Prepaid expenses and other	350	524
Accounts payable – trade	693	(1,423)
Accrued liabilities, other current liabilities and other liabilities	(983)	(1,571)
Total adjustments	8,798	1,348
Net cash provided by (used in) operating activities	20,064	(6,472)
Cash flows from investing activities:
Capital expenditures	(943)	(653)
Security deposits and other	2
Net cash used in investing activities	(941)	(653)
Cash flows from financing activities:
Net proceeds from issuance of common stock		5,341
Proceeds from borrowings under Credit Agreement	44,378	43,362
Repayments under Credit Agreement	(44,378)	(43,362)
Installment loan and capital lease obligation payments	(258)	(230)
Proceeds from the exercise of stock options	66
Net cash (used in) provided by financing activities	(192)	5,111
Effect of exchange rate changes on cash and cash equivalents	(24)	(95)
Increase (decrease) in cash and cash equivalents	18,907	(2,109)
Cash and cash equivalents - beginning of period	18,109	17,455
Cash and cash equivalents - end of period	$ 37,016	$ 15,346

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jan. 31, 2016
Disclosure Text Block [Abstract]
Basis of Accounting [Text Block]	Note 1 – Basis of Presentation The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Enzo Clinical Labs, Enzo Therapeutics and Enzo Realty LLC, collectively or with one or more of its subsidiaries referred to as the “Company” or “Companies”. The consolidated balance sheet as of January 31, 2016, the consolidated statements of operations, comprehensive income (loss), and cash flows for the three and six months ended January 31, 2016 and 2015, and the consolidated statement of stockholders’ equity for the six months ended January 31, 2016 are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted. The consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended July 31, 2015 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2015 has been derived from the audited financial statements at that date. The results of operations for the three and six months ended January 31, 2016 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2016. Effect of New Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02 – Leases (Topic 842). The objective of the update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The amendments of the ASU are effective for fiscal years beginning after December 31, 2018 and early application is permitted. We are currently evaluating the impact of this standard on our consolidated financial statements. In May 2014, the FASB issued Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, which supersedes ASC 605, Revenue Recognition. The new standard requires companies to recognize revenues upon transfer of goods or services to customers in amounts that reflect the consideration which the company expects to receive in exchange for those goods or services. In July 2015, the FASB delayed the effective date of the standard by one year. The new guidance is effective for financial statements issued for annual reporting periods beginning after December 15, 2017 and early application is not permitted before the original effective date of annual reporting periods beginning after December 15, 2016. We are currently evaluating the impact of this standard on our consolidated financial statements.

Net income (loss) per share

Net income (loss) per share	6 Months Ended
	Jan. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 2 – Net income (loss) per share Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. As a result of the net loss for the three and six months ended January 31, 2015, diluted weighted average shares outstanding are the same as basic weighted average shares outstanding, and do not include the potential common shares from stock options and unvested restricted stock because to do so would be antidilutive. For the three and six months ended January 31, 2016, approximately 440,000 and 281,000 weighted average stock options were included in the calculation of diluted weighted average shares outstanding. For the three and six months ended January 31, 2015, the number of potential common shares (“in the money options”) and unvested restricted stock excluded from the calculation of diluted earnings per share were zero and 18,000. For the three and six months ended January 31, 2016, the effect of approximately 235,000 and 305,000 respectively, of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income (loss) per share because their effect would be anti-dilutive. For the three and six months ended January 31, 2015, the effect of approximately 52,000 and 97,000 respectively, of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income (loss) per share because their effect would be anti-dilutive.

Supplemental disclosure for sta

Supplemental disclosure for statement of cash flows	6 Months Ended
	Jan. 31, 2016
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	Note 3 - Supplemental disclosure for statement of cash flows For the six months ended January 31, 2016 and 2015, income taxes paid by the Company were $53 and $37, respectively . For the six months ended January 31, 2016 and 2015, interest paid by the Company was $77 and $101, respectively. For the six months ended January 31, 2016 and 2015, the Company financed $76 and $57 respectively, in machinery and transportation equipment under installment loans. During the six months ended January 31, 2016 and 2015, there was a total of $1,141 and $155 in capital lease agreements.

Inventories

Inventories	6 Months Ended
	Jan. 31, 2016
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Note 4 - Inventories Inventories consist of the following: January 31, July 31, Raw materials $ 1,180 $ 1,013 Work in process 1,975 2,002 Finished products 4,240 4,381 $ 7,395 $ 7,396

Goodwill and intangible assets

Goodwill and intangible assets	6 Months Ended
	Jan. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	Note 5 – Goodwill and intangible assets At January 31, 2016 and July 31, 2015, the Company’s net carrying amount of goodwill, related to the Clinical Labs segment, is $7,452. The Company’s change in the net carrying amount of intangible assets, all in the Life Sciences segment is as follows: Gross Accumulated Amortization Net July 31, 2015 $ 27,838 $ (21,683 ) $ 6,155 Amortization expense — (843 ) (843 ) Foreign currency translation (350 ) 259 (91 ) January 31, 2016 $ 27,488 $ (22,267 ) $ 5,221 Intangible assets, all finite lived, consist of the following: January 31, 2016 July 31, 2015 Gross Accumulated Amortization Net Gross Accumulated Amortization Net Patents $ 11,027 $ (10,888 ) $ 139 $ 11,028 $ (10,871 ) $ 157 Customer relationships 12,046 (7,785 ) 4,261 12,243 (7,398 ) 4,845 Website and acquired content 1,006 (1,006 ) — 1,020 (1,020 ) — Licensed technology and other 499 (437 ) 62 518 (441 ) 77 Trademarks 2,910 (2,151 ) 759 3,029 (1,953 ) 1,076 Total $ 27,488 $ (22,267 ) $ 5,221 $ 27,838 $ (21,683 ) $ 6,155 At January 31, 2016, information with respect to intangibles assets acquired is as follows: Useful life assigned Weighted average remaining useful life Customer relationships 8-15 years 4.5 years Trademarks 5 years 1.5 years Other intangibles 10 years 3.5 years At January 31, 2016, the weighted average useful life of amortizable intangible assets is approximately four years.

Loan Payable

Loan Payable	6 Months Ended
	Jan. 31, 2016
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 6 - Loan Payable On June 7, 2013, the Company entered into a secured Revolving Loan and Security Agreement (the “Credit Agreement”) among the Company and certain of its subsidiaries, with Enzo Therapeutics as a guarantor, and Healthcare Finance Group, LLC (the “Lender).The Credit Agreement, which expires in December 2016, provides for borrowings against eligible US receivables, as defined, of the Clinical Lab and Life Science segments up to $8.0 million at defined eligibility percentages and provides for additional borrowings of $4.0 million for increased eligible assets. Debt issuance costs of $281 are being amortized over the life of the Credit Agreement. If the amount of borrowings outstanding under the revolving credit facility exceeds the borrowing base then in effect, or the Lender requires a reserve, the Company will be required to repay such borrowings in an amount sufficient to eliminate such excess. Interest on advances, payable monthly, is based on the three month LIBOR rate, with a floor of 1.25% plus an applicable margin of 4.0%. In the event of any default, the interest rate may be increased 3.0% over the current rate. The facility also carries a non-utilization fee of 0.50% per annum, payable monthly, on the unused portion of the Credit Agreement. At each of January 31, 2016 and July 31, 2015, the borrowings under the Credit Agreement related to the Clinical Labs and Life Sciences receivables aggregated $3.0 million. The Company’s obligations under the Credit Agreement are secured by primarily all the unencumbered U.S. assets of the Company, excluding buildings and intellectual property which the Lender has a negative pledge, and the capital stock of subsidiaries. The Credit Agreement includes customary affirmative and negative covenants and events of default and requires maximum levels of cash usage and minimum levels of liquidity, as defined, and provides for increased liquidity levels if operating results are not achieved. Negative covenants include among others, limitations on additional debt, liens, loans or investments, distributions, asset sales and affiliate transactions. Events of default include non-payment of principal and interest on debt outstanding, non-performance of covenants, material change in business, breach of representations, bankruptcy and insolvency, material judgments and changes in control. In July 31, 2013, the lender modified various financial covenants relating to fiscal 2014. As of January 31, 2016, the Company is in compliance with the financial covenants. The Credit Agreement includes customary affirmative and negative covenants and events of default. The terms of the debt covenants include: o The minimum balance the Company must borrow at any time is $2.0 million. At January 31 2016, the loan balance was approximately $3.0 million, with an additional availability of $3.9 million. o The Company must maintain a Minimum Liquidity, as defined in the Credit Agreement, of not less than $3.0 million. At January 31, 2016, the Company’s Minimum Liquidity was $8.9 million. o The quarterly Cash Burn, as defined in the Credit Agreement, must be greater than zero. During the six months ended January 31, 2016, the Cash Burn was positive in the amount of $0.1 million. As of October 31, 2015, the Credit Agreement was amended to redefine Cash Burn and add a definition for Liquidity (the “amendment”). Under the amendment, the determination of Cash Burn during a fiscal quarter excludes capital expenditures provided that Liquidity exceeds $7 million as of the last day of the fiscal quarter. As of January 31, 2016, Liquidity as defined was $37.9 million. Based on its current level of Minimum Liquidity and Cash Burn, the Company believes it will continue to be in compliance with the financial covenants in future periods; however there are no assurances of such compliance. Based on our ability to comply with financial covenants in the past, our ability to obtain covenant waivers previously, and our expected future performance, we believe we would be able to cure a non-compliance event and obtain a Lender waiver. The Company currently believes that the Lender would be willing to negotiate and provide waivers to the Company in the event of non-compliance with covenants, although there can be no assurances. In addition, the Company believes the effects of non-compliance with the covenants would not have a material effect on our financial condition and liquidity due to cash provided by operating cash flows and funds available under the Company’s Controlled Equity Offering program.

Accrued Liabilities and Other C

Accrued Liabilities and Other Current Liabilities	6 Months Ended
	Jan. 31, 2016
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 7 – Accrued Liabilities and Other Current Liabilities Accrued liabilities consist of the following: January 31, July 31, Payroll, benefits, and commissions $ 3,837 $ 3,907 Legal fee expense 2,320 4,183 Professional fees 485 678 Research and development 300 300 Other 2,614 2,229 $ 9,556 $ 11,297 Other current liabilities consist of the following: January 31, July 31, Accrued legal settlement $ 1,908 $ 406 Capital lease obligations 289 149 Installment loans 279 331 $ 2,476 $ 886

Other Liabilities

Other Liabilities	6 Months Ended
	Jan. 31, 2016
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Other Liabilities Disclosure [Text Block]	Note 8 – Other Liabilities Other liabilities consist of the following: January 31, July 31, Accrued legal settlement $ 800 $ 1,220 Capital lease obligations, net of short term 923 210 Installment loans, net of short term 202 363 $ 1,925 $ 1,793 As of January 31, 2016, future minimum payments under the capital leases, net of interest of $253 aggregates $1,212 including a short term debt portion of $289 included in other current liabilities. A total of $2.7 million is included in other current liabilities and in other liabilities as accrued legal settlement which is further discussed in Note 13 - Contingencies.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jan. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 9 – Stockholders’ Equity Controlled Equity Offering On March 28, 2013, the Company entered into a Controlled Equity Offering SM On December 31, 2014, the Sales Agreement was amended in order for the Company to offer and sell, through Cantor, acting as agent, additional shares of Common Stock having an aggregate offering price of $20.0 million. In connection with the amendment to the Sales Agreement, the Company also filed with the SEC a prospectus supplement dated December 31, 2014. During the six months ended January 31, 2016, the Company did not sell any shares of Common Stock under the Sales Agreement. For the six months ended January 31, 2015, the Company sold an aggregate of 1,126,804 shares of Common Stock under the Sales Agreement at an average price of $4.89 per share and received proceeds of approximately $5.3 million, net of expenses of $169. Share-based compensation The Company has an incentive stock option and restricted stock award plan (the “2005 Plan”), and a long term incentive share award plan, (the “2011 Incentive Plan”), which are more fully described in Note 10 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2015. The 2011 Plan, which is the only plan from which awards may now be granted, provides for the award to eligible employees, officers, directors, consultants and other persons of stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, performance awards, and other stock-based awards. The amounts of share-based compensation expense recognized in the periods presented are as follows: Three months ended Six months ended 2016 2015 2016 2015 Stock options $ 104 $ 91 $ 208 $ 176 Restricted stock 6 14 13 27 $ 110 $ 105 $ 221 $ 203 The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: Three months ended Six months ended 2016 2015 2016 2015 Cost of clinical laboratory services $ 2 $ 2 $ 3 $ 3 Research and development — 1 — 2 Selling, general and administrative 108 102 218 198 $ 110 $ 105 $ 221 $ 203 No excess tax benefits were recognized during the three month periods ended January 31, 2016 and 2015. Stock Option Plans The following table summarizes stock option activity during the three month period ended January 31, 2016: Options Weighted Weighted Aggregate Outstanding at July 31, 2015 1,358,104 $ 3.04 Awarded 189,873 $ 4.66 Exercised (23,702 ) $ 2.79 Cancelled or expired (6,000 ) $ 3.61 Outstanding at end of period 1,518,275 $ 3.25 2.0 years $ 2,269 Exercisable at end of period 1,098,307 $ 2.95 1.4 years $ 1,963 As of January 31, 2016, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $0.6 million and the weighted average period over which the remaining expense of these awards is expected to be recognized is seventeen months. The intrinsic value of in the money stock option awards that are vested at the end of the period represents the Company’s closing stock price on the last trading day of the period in excess of the exercise price multiplied by the number of options that vested. Restricted Stock Awards A summary of the activity pursuant to the Company’s unvested restricted stock awards for the six months ended January 31, 2016 is as follows: Awards Weighted Outstanding at July 31, 2015 21,501 $ 8.84 Awarded — $ — Vested (6,751 ) $ (2.10 ) Forfeited (1,500 ) $ (2.86 ) Unvested at end of period 13,250 $ 4.04 The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of January 31, 2016, there was approximately $0.1 million of unrecognized compensation cost related to unvested restricted stock-based compensation to be recognized over a weighted average remaining period of approximately eighteen months. The fair value of the awards that vested during the six months ended January 31, 2016 and 2015 was $21 and $43, respectively. The total number of shares available for grant as equity awards from the 2011 Incentive Plan is approximately 1,118,000 shares as of January 31, 2016.

Income taxes

Income taxes	6 Months Ended
	Jan. 31, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 10 - Income taxes At the end of each interim reporting period, the Company estimates its effective income tax rate expected to be applicable for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis and may change in subsequent interim periods. The Company’s effective tax rate (provision) for the three months ended January 31, 2016 was (2.9%) compared to a benefit of 2.7% for the three months ended January 31, 2015. The Company’s effective tax rate (provision) was (2.5%) and deminimus for the six months ended January 31, 2016 and 2015, respectively. The tax provision for the periods was based on state, local and foreign taxes, net of the benefit for amortization of foreign intangibles. The Company’s effective tax rate for both periods differed from the expected net operating loss carryforward benefit at the U.S. federal statutory rate of 34% primarily due to the inability to recognize such benefit. The carryforward benefit cannot be recognized because of uncertainties relating to future taxable income in terms of both its timing and its sufficiency, which would enable the Company to realize the federal carryforward benefit. The Company files a consolidated Federal income tax return. The Company files combined returns with California, Michigan and New York State and City for certain subsidiaries. Other subsidiaries file separate state and foreign tax returns.

Royalty and licensing income

Royalty and licensing income	6 Months Ended
	Jan. 31, 2016
Royalty And Licensing Income [Abstract]
Royalty And Licensing Income [Text Block]	Note 11 – Royalty and licensing income The Company’s Life Science segment has a license agreement with Qiagen that began in 2005, whereby the Company earns quarterly royalties on the net sales of Qiagen products subject to the license until the expiration of the patent on April 24, 2018. During the six months ended January 31, 2016 and 2015, the Company recorded royalty income under the agreement of approximately $0.9 million and $1.6 million respectively, which is included in the Life Sciences segment.

Segment reporting

Segment reporting	6 Months Ended
	Jan. 31, 2016
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	Note 12 – Segment reporting The Company has three reportable segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides diagnostic services to the health care community. The Company’s Life Sciences segment develops, manufactures, and markets products to research and pharmaceutical customers. The Company’s Therapeutic segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments. Legal fee expense incurred to defend the Company’s intellectual property and other general corporate matters is considered a component of the Other segment. Legal fee expense specific to other segments’ activities has been allocated to those segments. Legal settlements, net represent activities for which royalties would have been received by the Company’s Life Sciences segment had the Company had agreements in place with plaintiffs for the patents or products covered by the settlements. Management of the Company assesses assets on a consolidated basis only and, therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended July 31, 2015. The following financial information represents the operating results of the reportable segments of the Company: Three months ended January 31, 2016 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 17,523 — — — $ 17,523 Product revenues — $ 6,578 — — 6,578 Royalty and license fee income — 459 — — 459 17,523 7,037 — — 24,560 Operating expenses: Cost of clinical laboratory services 10,535 — — — 10,535 Cost of product revenues — 3,206 — — 3,206 Research and development — 661 $ 200 — 861 Selling, general and administrative 5,649 2,773 — $ 2,858 11,280 Provision for uncollectible accounts receivable 467 (8 ) — — 459 Legal fee expense 57 5 — 2,349 2,411 Legal settlements, net 1,500 (13,150 ) — — (11,650 ) Total operating expenses 18,208 (6,513 ) 200 5,207 17,102 Operating income (loss) (685 ) 13,550 (200 ) (5,207 ) 7,458 Other income (expense) Interest (23 ) 17 — (36 ) (42 ) Other (1 ) — — 12 11 Foreign exchange loss — (388 ) — — (388 ) Income (loss) before income taxes $ (709 ) $ 13,179 $ (200 ) $ (5,231 ) $ 7,039 Depreciation and amortization included above $ 411 $ 524 $ — $ 17 $ 952 Share-based compensation included in above: Cost of clinical laboratory services $ 2 — — — $ 2 Research and development — — — — — Selling, general and administrative 9 $ 5 — $ 94 108 Total $ 11 $ 5 $ — $ 94 $ 110 Capital expenditures $ 354 $ 84 $ — $ — $ 438 Three months ended January 31, 2015 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 14,725 — — — $ 14,725 Product revenues — $ 7,723 — — 7,723 Royalty and license fee income — 644 — — 644 14,725 8,367 — — 23,092 Operating expenses: Cost of clinical laboratory services 9,246 — — — 9,246 Cost of product revenues — 3,818 — — 3,818 Research and development — 635 $ 199 — 834 Selling, general and administrative 5,089 2,704 — $ 1,877 9,670 Provision for uncollectible accounts receivable 658 (57 ) — — 601 Legal fee expense 41 (53 ) — 2,816 2,804 Total operating expenses 15,034 7,047 199 4,693 26,973 Operating income (loss) (309 ) 1,320 (199 ) (4,693 ) (3,881 ) Other income (expense) Interest (12 ) 5 — (42 ) (49 ) Other 4 (29 ) — 8 (17 ) Foreign exchange loss — (259 ) — — (259 ) Income (loss) before income taxes $ (317 ) $ 1,037 $ (199 ) $ (4,727 ) $ (4,206 ) Depreciation and amortization included above $ 357 $ 555 $ 1 $ 22 $ 935 Share-based compensation included in above: Cost of clinical laboratory services $ 2 — — — $ 2 Research and development — $ 1 — — 1 Selling, general and administrative 12 3 — $ 87 102 Total $ 14 $ 4 $ — $ 87 $ 105 Capital expenditures $ 338 $ 51 $ — $ — $ 389 Six months ended January 31, 2016 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 34,613 — — — $ 34,613 Product revenues — $ 14,265 — — 14,265 Royalty and license fee income — 859 — — 859 34,613 15,124 — — 49,737 Operating expenses: Cost of clinical laboratory services 20,867 — — — 20,867 Cost of product revenues — 6,817 — — 6,817 Research and development — 1,328 $ 400 — 1,728 Selling, general and administrative 10,935 5,832 — $ 4,738 21,505 Provision for uncollectible accounts receivable 1,175 (12 ) — — 1,163 Legal fee expense 66 (17 ) — 3,963 4,012 Legal settlements, net 1,500 (19,950 ) — — (18,450 ) Total operating expenses 34,543 (6,002 ) 400 8,701 37,642 Operating income (loss) 70 21,126 (400 ) (8,701 ) 12,095 Other income (expense) Interest (42 ) 31 — (71 ) (82 ) Other 3 39 — 23 65 Foreign exchange loss — (518 ) — — (518 ) Income (loss) before income taxes $ 31 $ 20,678 $ (400 ) $ (8,749 ) $ 11,560 Depreciation and amortization included above $ 808 $ 1,054 $ — $ 40 $ 1,902 Share-based compensation included in above: Cost of clinical laboratory services $ 3 — — — $ 3 Research and development — — — — — Selling, general and administrative 19 $ 10 — $ 189 218 Total $ 22 $ 10 $ — $ 189 $ 221 Capital expenditures $ 791 $ 152 $ — $ — $ 943 Six months ended January 31, 2015 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 30,547 — — — $ 30,547 Product revenues — $ 15,725 — — 15,725 Royalty and license fee income — 1,644 — — 1,644 30,547 17,369 — — 47,916 Operating expenses: Cost of clinical laboratory services 19,376 — — — 19,376 Cost of product revenues — 7,513 — — 7,513 Research and development — 1,183 $ 442 — 1,625 Selling, general and administrative 10,157 5,853 — $ 3,945 19,955 Provision for uncollectible accounts receivable 1,189 (47 ) — — 1,142 Legal fee expense 131 (51 ) — 5,190 5,270 Total operating expenses 30,853 14,451 442 9,135 54,881 Operating income (loss) (306 ) 2,918 (442 ) (9,135 ) (6,965 ) Other income (expense) Interest (39 ) 7 — (86 ) (118 ) Other 6 (35 ) — 31 2 Foreign exchange gain — (731 ) — — (731 ) Income (loss) before income taxes $ (339 ) $ 2,159 $ (442 ) $ (9,190 ) $ (7,812 ) Depreciation and amortization included above $ 714 $ 1,113 $ 2 $ 44 $ 1,873 Share-based compensation included in above: Cost of clinical laboratory services $ 3 — — — $ 3 Research and development — $ 2 — — 2 Selling, general and administrative 21 3 — $ 174 198 Total $ 24 $ 5 $ — $ 174 $ 203 Capital expenditures $ 589 $ 64 $ — $ — $ 653

Contingencies

Contingencies	6 Months Ended
	Jan. 31, 2016
Loss Contingency [Abstract]
Contingencies Disclosure [Text Block]	Note 13 – Contingencies On June 7, 2004, the Company and Enzo Life Sciences, Inc., filed suit in the United States District Court for the District of Connecticut against Applera Corporation and its wholly-owned subsidiary Tropix, Inc., which became Life Technologies, Inc. (NASDAQ:LIFE) and was acquired by Thermo Fisher Scientific, Inc. (NYSE:TMO) on February 3, 2014. The complaint alleged infringement of six patents relating to DNA sequencing systems, labeled nucleotide products, and other technology. Yale University is the owner of four of the patents and the Company is the exclusive licensee. These four patents are commonly referred to as the “Ward” patents. On November 12, 2012, a jury in New Haven found that one of these patents (United States Patent No. 5,449,667) was infringed and not proven invalid. The jury awarded $48.5 million for this infringement. On January 6, 2014, the judge awarded prejudgment interest of approximately $12.5 million and additional post-interest on the full amount will also be awarded starting November 7, 2012 until the total award is satisfied. The final award to the Company could be reduced or be subject to possible claims from third parties. On March 16, 2015, the Court of Appeals for the Federal Circuit vacated that judgment in a decision remanding the matter to the district court for further proceedings. On February 22, 2016, the Connecticut District Court granted Applera’s motion for summary judgment of non-infringement. The Company intends to appeal that decision. There can be no assurance that the Company will be successful in this litigation. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company. As of August 1, 2014 the Company was engaged in litigation in the United States District Court for the Southern District of New York against Roche Diagnostic GmbH and its related company Roche Molecular Systems, Inc. (“Roche”), as declaratory judgment defendant. This case was commenced in May 2004. Roche seeks a declaratory judgment of non-breach of contract and patent invalidity against the Company. Roche has also asserted tort claims against the Company. The Company has asserted breach of contract and patent infringement causes of action against Roche. There has been extensive discovery in the case. In 2011, Roche moved for summary judgment of non-infringement regarding the Company’s patent claims. In 2012, the motion was granted in part and denied in part. In December 2012, Roche moved for summary judgment on the Company’s non-patent claims. Additional discovery was taken and the Company responded to the motions in May 2013. On December 6, 2013, the Court granted in part and denied in part Roche’s summary judgment motion. On October 22, 2014, the Court ordered that damages discovery concerning the Company’s remaining contract and patent claims and Roche’s claims should be completed by January 30, 2015, and expert discovery should be completed following the Court’s not-yet-issued claim construction ruling concerning the Company’s patent infringement claim against Roche. Roche dropped its tort claims during damages discovery. On April 28, 2015, the Court heard oral argument on claim construction issues. On May 8, 2015, Roche and the Company jointly moved the Court to extend the schedule for damages discovery until May 29, 2015, and the Court granted that motion. The litigation in the United States District Court for the Southern District of New York between the Company and Molecular Probes, Inc. terminated on May 11, 2015, with a settlement, upon the parties’ joint stipulation for dismissal. On April 22, 2014, the Company as plaintiff finalized and executed a settlement agreement with Affymetrix, Inc. to settle patent litigation actions before the U.S. District Court, Southern District of New York (the “Agreement”) in the amount of $5.1 million. Under terms of the Agreement, Affymetrix paid to the Company $4.3 million and paid to the Company’s attorneys $0.8 million. On June 20, 2014, the Company, as plaintiff finalized and executed a settlement agreement with PerkinElmer, Inc., and PerkinElmer Health Sciences, Inc. (formerly known as PerkinElmer Life Sciences, Inc.) (together, “PerkinElmer”), with respect to an action between the Company and PerkinElmer before the U.S. District Court, Southern District of New York, Case No 03-CV-3817. PerkinElmer paid $7.0 million in escrow pursuant to the agreement because of a former attorney’s charging lien for fees allegedly owed for past services rendered to the Company. Also put into escrow was an additional $30 relating to the Molecular Probes settlement. On December 3, 2015, the Company entered into a Settlement Agreement with the former attorney pursuant to which the Company and the former attorney resolved their respective claims against each other. During the three months ended January 31, 2016, the Company received a total of $7.03 million from the escrow referred to above in accordance with the terms of the Settlement Agreement. This settlement is included in the statement of operations under Legal settlements, net within the Life Science segment. In 2012, the Company received a Subpoena Duces Tecum (the “Subpoena”) from the Department of Health and Human Services, Office of Inspector General (“OIG”). The Subpoena was issued as part of an investigation being conducted by the US Attorney’s Office for the Eastern District of New York in conjunction with the OIG. While a number of potential issues were raised initially by the government, the investigation came to focus primarily on an alleged failure to collect diagnosis codes from physicians who ordered tests through Enzo Clinical Labs. The time period initially covered by the investigation was from 2004 through 2011. In response to the Subpoena, the Company cooperated with the government. On September 22, 2014, the Company and the U.S. Department of Justice reached a settlement agreement to resolve this matter, in substantive form as disclosed in the Company’s fiscal quarter ended April 30, 2014. During the quarter ended April, 30, 2014, the Company recorded a charge of $2.0 million in the statement of operations under legal settlements, net within the Clinical Labs segment. The settlement amount will be paid with interest over a five-year period. Under certain circumstances, the Company may be required to accelerate payments and/or pay up to an additional $1.5 million based upon (i) a favorable recovery and collection related to the judgment in the Life Technologies matter discussed above, (ii) receipt of additional capital greater than $10.0 million in a fiscal year (in that case, the Company is required to pay 20% of any amount over $10.0 million plus interest, or (iii) sale of the Company. The final settlement covers the time period 2004-2014. During the three months ended January 31, 2016, the Company accrued an additional $1.5 million, due to the Company’s achievement of certain financial milestones. As of January 31, 2016, the total liability for this settlement is $2.7 million, of which $1.9 million is included in other current liabilities and $0.8 million included in other liabilities. On July 2, 2015, the Company as Plaintiff executed a settlement agreement with Luminex Corporation with respect to an action between the Company and Abbott Laboratories and Abbott Molecular, Inc (Defendants) and Luminex Corporation (Intervening Defendant) before the United States District Court for the District of Delaware for alleged patent infringement. Luminex paid the Company a total of $7.1 million as consideration for this agreement and the dismissal of the litigation against Luminex. On July 20, 2015, the Company as a Plaintiff finalized and executed a settlement agreement with Siemens Healthcare Diagnostics Inc. (“Siemens”) to settle a patent litigation lawsuit before the U.S. District Court for the District of Delaware in the amount of $6.7 million, net. Under terms of the agreement, Siemens will also pay the Company additional royalties of $1.0 million per annum on sales of its molecular products manufactured and/or sold in the United States during the its fiscal years 2015 through 2019 if sales of such products exceed a contractual amount. The net settlement amount was included in other receivables in the consolidated balance sheet as of July 31, 2015 and was received in August 2015. On October 9, 2015, the Company reached and finalized a settlement with Affymetrix, Inc. in the amount of $6.8 million, net in a patent infringement action brought by the Company. On January 4, 2016, the Company reached and finalized a settlement agreement with Agilent Technologies, Inc. in the amount of $6.1 million, net in a patent infringement action brought by the Company. Both cases were originally brought by the Company in the United States District Court for the District of Delaware. The settlements are included in the statement of operations under Legal settlements, net within the Life Science segment. The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jan. 31, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories consist of the following: January 31, July 31, Raw materials $ 1,180 $ 1,013 Work in process 1,975 2,002 Finished products 4,240 4,381 $ 7,395 $ 7,396

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	6 Months Ended
	Jan. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	The Company’s change in the net carrying amount of intangible assets, all in the Life Sciences segment is as follows: Gross Accumulated Amortization Net July 31, 2015 $ 27,838 $ (21,683 ) $ 6,155 Amortization expense — (843 ) (843 ) Foreign currency translation (350 ) 259 (91 ) January 31, 2016 $ 27,488 $ (22,267 ) $ 5,221
Schedule of Intangible Assets [Table Text Block]	Intangible assets, all finite lived, consist of the following: January 31, 2016 July 31, 2015 Gross Accumulated Amortization Net Gross Accumulated Amortization Net Patents $ 11,027 $ (10,888 ) $ 139 $ 11,028 $ (10,871 ) $ 157 Customer relationships 12,046 (7,785 ) 4,261 12,243 (7,398 ) 4,845 Website and acquired content 1,006 (1,006 ) — 1,020 (1,020 ) — Licensed technology and other 499 (437 ) 62 518 (441 ) 77 Trademarks 2,910 (2,151 ) 759 3,029 (1,953 ) 1,076 Total $ 27,488 $ (22,267 ) $ 5,221 $ 27,838 $ (21,683 ) $ 6,155
Schedule of Useful Lives For Acquisitions [Table Text Block]	At January 31, 2016, information with respect to intangibles assets acquired is as follows: Useful life assigned Weighted average remaining useful life Customer relationships 8-15 years 4.5 years Trademarks 5 years 1.5 years Other intangibles 10 years 3.5 years

Accrued Liabilities and Other23

Accrued Liabilities and Other Current Liabilities (Tables)	6 Months Ended
	Jan. 31, 2016
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued liabilities consist of the following: January 31, July 31, Payroll, benefits, and commissions $ 3,837 $ 3,907 Legal fee expense 2,320 4,183 Professional fees 485 678 Research and development 300 300 Other 2,614 2,229 $ 9,556 $ 11,297
Schedule of Other Current Liabilities [Table Text Block]	Other current liabilities consist of the following: January 31, July 31, Accrued legal settlement $ 1,908 $ 406 Capital lease obligations 289 149 Installment loans 279 331 $ 2,476 $ 886

Other Liabilities (Tables)

Other Liabilities (Tables)	6 Months Ended
	Jan. 31, 2016
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Schedule of Other Liabilities [Table Text Block]	Other liabilities consist of the following: January 31, July 31, Accrued legal settlement $ 800 $ 1,220 Capital lease obligations, net of short term 923 210 Installment loans, net of short term 202 363 $ 1,925 $ 1,793

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jan. 31, 2016
Stockholders' Equity Note [Abstract]
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	The amounts of share-based compensation expense recognized in the periods presented are as follows: Three months ended Six months ended 2016 2015 2016 2015 Stock options $ 104 $ 91 $ 208 $ 176 Restricted stock 6 14 13 27 $ 110 $ 105 $ 221 $ 203
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: Three months ended Six months ended 2016 2015 2016 2015 Cost of clinical laboratory services $ 2 $ 2 $ 3 $ 3 Research and development — 1 — 2 Selling, general and administrative 108 102 218 198 $ 110 $ 105 $ 221 $ 203
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes stock option activity during the three month period ended January 31, 2016: Options Weighted Weighted Aggregate Outstanding at July 31, 2015 1,358,104 $ 3.04 Awarded 189,873 $ 4.66 Exercised (23,702 ) $ 2.79 Cancelled or expired (6,000 ) $ 3.61 Outstanding at end of period 1,518,275 $ 3.25 2.0 years $ 2,269 Exercisable at end of period 1,098,307 $ 2.95 1.4 years $ 1,963
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	A summary of the activity pursuant to the Company’s unvested restricted stock awards for the six months ended January 31, 2016 is as follows: Awards Weighted Outstanding at July 31, 2015 21,501 $ 8.84 Awarded — $ — Vested (6,751 ) $ (2.10 ) Forfeited (1,500 ) $ (2.86 ) Unvested at end of period 13,250 $ 4.04

Segment reporting (Tables)

Segment reporting (Tables)	6 Months Ended
	Jan. 31, 2016
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	The following financial information represents the operating results of the reportable segments of the Company: Three months ended January 31, 2016 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 17,523 — — — $ 17,523 Product revenues — $ 6,578 — — 6,578 Royalty and license fee income — 459 — — 459 17,523 7,037 — — 24,560 Operating expenses: Cost of clinical laboratory services 10,535 — — — 10,535 Cost of product revenues — 3,206 — — 3,206 Research and development — 661 $ 200 — 861 Selling, general and administrative 5,649 2,773 — $ 2,858 11,280 Provision for uncollectible accounts receivable 467 (8 ) — — 459 Legal fee expense 57 5 — 2,349 2,411 Legal settlements, net 1,500 (13,150 ) — — (11,650 ) Total operating expenses 18,208 (6,513 ) 200 5,207 17,102 Operating income (loss) (685 ) 13,550 (200 ) (5,207 ) 7,458 Other income (expense) Interest (23 ) 17 — (36 ) (42 ) Other (1 ) — — 12 11 Foreign exchange loss — (388 ) — — (388 ) Income (loss) before income taxes $ (709 ) $ 13,179 $ (200 ) $ (5,231 ) $ 7,039 Depreciation and amortization included above $ 411 $ 524 $ — $ 17 $ 952 Share-based compensation included in above: Cost of clinical laboratory services $ 2 — — — $ 2 Research and development — — — — — Selling, general and administrative 9 $ 5 — $ 94 108 Total $ 11 $ 5 $ — $ 94 $ 110 Capital expenditures $ 354 $ 84 $ — $ — $ 438 Three months ended January 31, 2015 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 14,725 — — — $ 14,725 Product revenues — $ 7,723 — — 7,723 Royalty and license fee income — 644 — — 644 14,725 8,367 — — 23,092 Operating expenses: Cost of clinical laboratory services 9,246 — — — 9,246 Cost of product revenues — 3,818 — — 3,818 Research and development — 635 $ 199 — 834 Selling, general and administrative 5,089 2,704 — $ 1,877 9,670 Provision for uncollectible accounts receivable 658 (57 ) — — 601 Legal fee expense 41 (53 ) — 2,816 2,804 Total operating expenses 15,034 7,047 199 4,693 26,973 Operating income (loss) (309 ) 1,320 (199 ) (4,693 ) (3,881 ) Other income (expense) Interest (12 ) 5 — (42 ) (49 ) Other 4 (29 ) — 8 (17 ) Foreign exchange loss — (259 ) — — (259 ) Income (loss) before income taxes $ (317 ) $ 1,037 $ (199 ) $ (4,727 ) $ (4,206 ) Depreciation and amortization included above $ 357 $ 555 $ 1 $ 22 $ 935 Share-based compensation included in above: Cost of clinical laboratory services $ 2 — — — $ 2 Research and development — $ 1 — — 1 Selling, general and administrative 12 3 — $ 87 102 Total $ 14 $ 4 $ — $ 87 $ 105 Capital expenditures $ 338 $ 51 $ — $ — $ 389 Six months ended January 31, 2016 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 34,613 — — — $ 34,613 Product revenues — $ 14,265 — — 14,265 Royalty and license fee income — 859 — — 859 34,613 15,124 — — 49,737 Operating expenses: Cost of clinical laboratory services 20,867 — — — 20,867 Cost of product revenues — 6,817 — — 6,817 Research and development — 1,328 $ 400 — 1,728 Selling, general and administrative 10,935 5,832 — $ 4,738 21,505 Provision for uncollectible accounts receivable 1,175 (12 ) — — 1,163 Legal fee expense 66 (17 ) — 3,963 4,012 Legal settlements, net 1,500 (19,950 ) — — (18,450 ) Total operating expenses 34,543 (6,002 ) 400 8,701 37,642 Operating income (loss) 70 21,126 (400 ) (8,701 ) 12,095 Other income (expense) Interest (42 ) 31 — (71 ) (82 ) Other 3 39 — 23 65 Foreign exchange loss — (518 ) — — (518 ) Income (loss) before income taxes $ 31 $ 20,678 $ (400 ) $ (8,749 ) $ 11,560 Depreciation and amortization included above $ 808 $ 1,054 $ — $ 40 $ 1,902 Share-based compensation included in above: Cost of clinical laboratory services $ 3 — — — $ 3 Research and development — — — — — Selling, general and administrative 19 $ 10 — $ 189 218 Total $ 22 $ 10 $ — $ 189 $ 221 Capital expenditures $ 791 $ 152 $ — $ — $ 943 Six months ended January 31, 2015 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 30,547 — — — $ 30,547 Product revenues — $ 15,725 — — 15,725 Royalty and license fee income — 1,644 — — 1,644 30,547 17,369 — — 47,916 Operating expenses: Cost of clinical laboratory services 19,376 — — — 19,376 Cost of product revenues — 7,513 — — 7,513 Research and development — 1,183 $ 442 — 1,625 Selling, general and administrative 10,157 5,853 — $ 3,945 19,955 Provision for uncollectible accounts receivable 1,189 (47 ) — — 1,142 Legal fee expense 131 (51 ) — 5,190 5,270 Total operating expenses 30,853 14,451 442 9,135 54,881 Operating income (loss) (306 ) 2,918 (442 ) (9,135 ) (6,965 ) Other income (expense) Interest (39 ) 7 — (86 ) (118 ) Other 6 (35 ) — 31 2 Foreign exchange gain — (731 ) — — (731 ) Income (loss) before income taxes $ (339 ) $ 2,159 $ (442 ) $ (9,190 ) $ (7,812 ) Depreciation and amortization included above $ 714 $ 1,113 $ 2 $ 44 $ 1,873 Share-based compensation included in above: Cost of clinical laboratory services $ 3 — — — $ 3 Research and development — $ 2 — — 2 Selling, general and administrative 21 3 — $ 174 198 Total $ 24 $ 5 $ — $ 174 $ 203 Capital expenditures $ 589 $ 64 $ — $ — $ 653

Net income (loss) per share (De

Net income (loss) per share (Details) - shares	3 Months Ended		6 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2016	Jan. 31, 2015
Weighted Average Stock Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Included In Computation Of Earnings Per Share Amount	440,000		281,000
In the Money Stock Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		0		18,000
Unvested Restricted Stock [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		0		18,000
Outstanding Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	235,000	52,000	305,000	97,000

Supplemental disclosure for s28

Supplemental disclosure for statement of cash flows (Details) - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2016	Jan. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Income Taxes Paid	$ 53	$ 37
Interest Paid	77	101
Installment Loans Financed Amount	76	57
Capital Lease Obligation Cost Basis	$ 1,141	$ 155

Inventories (Details) - Schedul

Inventories (Details) - Schedule of inventory, current - USD ($) $ in Thousands	Jan. 31, 2016	Jul. 31, 2015
Schedule of inventory, current [Abstract]
Raw materials	$ 1,180	$ 1,013
Work in process	1,975	2,002
Finished products	4,240	4,381
	$ 7,395	$ 7,396

Goodwill and intangible asset30

Goodwill and intangible assets (Details) - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2016	Jul. 31, 2015
Goodwill and intangible assets (Details) [Line Items]
Goodwill	$ 7,452	$ 7,452
Intangible Assets, Amortization Period [Member]
Goodwill and intangible assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	4 years

Goodwill and intangible asset31

Goodwill and intangible assets (Details) - Schedule of indefinite-lived intangible assets - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2016	Jan. 31, 2015
Indefinite-lived Intangible Assets [Line Items]
July 31, 2015	$ 27,838
July 31, 2015	(21,683)
July 31, 2015	6,155
Amortization expense	(843)	$ (859)
Amortization expense	(843)	$ (859)
January 31, 2016	27,488
January 31, 2016	(22,267)
January 31, 2016	5,221
Life Sciences [Member]
Indefinite-lived Intangible Assets [Line Items]
July 31, 2015	27,838
July 31, 2015	(21,683)
July 31, 2015	6,155
Amortization expense	(843)
Amortization expense	(843)
Foreign currency translation	(350)
Foreign currency translation	259
Foreign currency translation	(91)
January 31, 2016	27,488
January 31, 2016	(22,267)
January 31, 2016	$ 5,221

Goodwill and intangible asset32

Goodwill and intangible assets (Details) - Schedule of intangible assets - USD ($) $ in Thousands	Jan. 31, 2016	Jul. 31, 2015
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	$ 27,488	$ 27,838
Finite-lived intangible assets, Accumulated Amortization	(22,267)	(21,683)
Finite-lived intangible assets, Net	5,221	6,155
Patents [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	11,027	11,028
Finite-lived intangible assets, Accumulated Amortization	(10,888)	(10,871)
Finite-lived intangible assets, Net	139	157
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	12,046	12,243
Finite-lived intangible assets, Accumulated Amortization	(7,785)	(7,398)
Finite-lived intangible assets, Net	4,261	4,845
Website And Acquired Content [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	1,006	1,020
Finite-lived intangible assets, Accumulated Amortization	(1,006)	(1,020)
Licensed Technology And Other [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	499	518
Finite-lived intangible assets, Accumulated Amortization	(437)	(441)
Finite-lived intangible assets, Net	62	77
Trademarks [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	2,910	3,029
Finite-lived intangible assets, Accumulated Amortization	(2,151)	(1,953)
Finite-lived intangible assets, Net	$ 759	$ 1,076

Goodwill and intangible asset33

Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions	6 Months Ended
	Jan. 31, 2016
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Weighted average remaining useful life	4 years 6 months
Trademarks [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	5 years
Weighted average remaining useful life	1 year 6 months
Other Intangible Assets [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	10 years
Weighted average remaining useful life	3 years 6 months
Minimum [Member] | Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	8 years
Maximum [Member] | Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	15 years

Loan Payable (Details)

Loan Payable (Details) - USD ($)	6 Months Ended
	Jan. 31, 2016	Oct. 31, 2015	Jul. 31, 2015
Debt Disclosure [Abstract]
Line of Credit Facility Expiration Month and Year	December 2,016
Line of Credit Facility, Maximum Borrowing Capacity	$ 8,000,000
Line of Credit Facility Additional Borrowings Capacity	4,000,000
Unamortized Debt Issuance Expense	$ 281,000
LIBOR Rate Period	3 months
Debt Instrument, Description of Variable Rate Basis	three month LIBOR rate, with a floor of 1.25% plus an applicable margin of 4.0%
Debt Instrument, Basis Spread on Variable Rate	1.25%
Debt Instrument Margin on Variable Rate	4.00%
Debt Instrument Increase in Interest Rate on Default	3.00%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.50%
Long-term Line of Credit	$ 3,013,000		$ 3,013,000
Line of Credit Facility Minimum Borrowings	2,000,000
Line of Credit Facility, Remaining Borrowing Capacity	3,900,000
Line of Credit Facility Minimum Liquidity Requirement	3,000,000
Line of Credit Facility Minimum Liquidity Current	8,900,000
Line of Credit Facility Minimum Cash Burn	0
Line of Credit Facility Cash Burn Current	100,000
Line of Credit Facility Minimum Cash Burn Excluding Capital Expenditures		$ 7,000,000
Line of Credit Facility Cash Burn Current Excluding Capital Expenditures	$ 37,900,000

Accrued Liabilities and Other35

Accrued Liabilities and Other Current Liabilities (Details) - Accrued liabilities - USD ($) $ in Thousands	Jan. 31, 2016	Jul. 31, 2015
Accrued liabilities [Abstract]
Payroll, benefits, and commissions	$ 3,837	$ 3,907
Legal fee expense	2,320	4,183
Professional fees	485	678
Research and development	300	300
Other	2,614	2,229
	$ 9,556	$ 11,297

Accrued Liabilities and Other36

Accrued Liabilities and Other Current Liabilities (Details) - Other current liabilities - USD ($) $ in Thousands	Jan. 31, 2016	Jul. 31, 2015
Accrued Liabilities and Other Current Liabilities (Details) - Other current liabilities [Line Items]
Other current liabilities	$ 2,476	$ 886
Accrued Legal Settlement [Member]
Accrued Liabilities and Other Current Liabilities (Details) - Other current liabilities [Line Items]
Other current liabilities	1,908	406
Capital Lease Obligations [Member]
Accrued Liabilities and Other Current Liabilities (Details) - Other current liabilities [Line Items]
Other current liabilities	289	149
Installment Loans [Member]
Accrued Liabilities and Other Current Liabilities (Details) - Other current liabilities [Line Items]
Other current liabilities	$ 279	$ 331

Other Liabilities (Details)

Other Liabilities (Details) - USD ($) $ in Thousands	Jan. 31, 2016	Jul. 31, 2015
Other Liabilities (Details) [Line Items]
Other Liabilities, Current	$ 2,476	$ 886
Accrued Legal Settlement	2,700
Capital Lease Obligation [Member] | Clinical Labs [Member]
Other Liabilities (Details) [Line Items]
Capital Leases, Future Minimum Payments, Interest Included in Payments	253
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments	1,212
Other Liabilities, Current	$ 289

Other Liabilities (Details) - S

Other Liabilities (Details) - Schedule of other liabilities - USD ($) $ in Thousands	Jan. 31, 2016	Jul. 31, 2015
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	$ 1,925	$ 1,793
Accrued Legal Settlement [Member]
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	800	1,220
Capital Lease Obligations [Member]
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	923	210
Installment Loans [Member]
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	$ 202	$ 363

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2016	Jan. 31, 2015	Jul. 31, 2015	Dec. 31, 2014
Stockholders' Equity (Details) [Line Items]
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$ 0.01		$ 0.01		$ 0.01
Maximum Offering Price Under Sales Agreement	$ 20,000,000		$ 20,000,000			$ 20,000,000
Percentage of Commission Payable on Equity Offering			3.00%
Proceeds from Issuance of Common Stock				$ 5,341,000
Excess Tax Benefit from Share-based Compensation, Financing Activities	0	$ 0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	600,000		$ 600,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			17 months
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 100,000		$ 100,000
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Remaining Contractual Terms			18 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value			$ 21,000	$ 43,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	1,118,000		1,118,000
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)				1,126,804
Average Sale Price of Stock (in Dollars per share)				$ 4.89
Stock Offering and Commissions Expenses				$ 169,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of share-based compensation expense - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2016	Jan. 31, 2015
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	$ 110	$ 105	$ 221	$ 203
Options [Member]
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	104	91	208	176
Restricted Stocks [Member]
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	$ 6	$ 14	$ 13	$ 27

Stockholders' Equity (Details41

Stockholders' Equity (Details) - Schedule of share-based compensation expense by line item - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2016	Jan. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	$ 110	$ 105	$ 221	$ 203
Cost of Clinical Laboratory Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	2	2	3	3
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement		1		2
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	$ 108	$ 102	$ 218	$ 198

Stockholders' Equity (Details42

Stockholders' Equity (Details) - Schedule of stock option plans $ / shares in Units, $ in Thousands	6 Months Ended
	Jan. 31, 2016USD ($)$ / sharesshares
Schedule of stock option plans [Abstract]
Outstanding at July 31, 2015 | shares	1,358,104
Outstanding at July 31, 2015 | $ / shares	$ 3.04
Awarded | shares	189,873
Awarded | $ / shares	$ 4.66
Exercised | shares	(23,702)
Exercised | $ / shares	$ 2.79
Cancelled or expired | shares	(6,000)
Cancelled or expired | $ / shares	$ 3.61
Outstanding at end of period | shares	1,518,275
Outstanding at end of period | $ / shares	$ 3.25
Outstanding at end of period	2 years
Outstanding at end of period | $	$ 2,269
Exercisable at end of period | shares	1,098,307
Exercisable at end of period | $ / shares	$ 2.95
Exercisable at end of period	1 year 146 days
Exercisable at end of period | $	$ 1,963

Stockholders' Equity (Details43

Stockholders' Equity (Details) - Schedule of restricted stock awards	6 Months Ended
	Jan. 31, 2016$ / sharesshares
Schedule of restricted stock awards [Abstract]
Outstanding at July 31, 2015 | shares	21,501
Outstanding at July 31, 2015 | $ / shares	$ 8.84
Vested | shares	(6,751)
Vested | $ / shares	$ (2.10)
Forfeited | shares	(1,500)
Forfeited | $ / shares	$ (2.86)
Unvested at end of period | shares	13,250
Unvested at end of period | $ / shares	$ 4.04

Income taxes (Details)

Income taxes (Details)	3 Months Ended		6 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2016	Jan. 31, 2015
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	2.90%	2.70%	2.50%	2.50%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent			34.00%

Royalty and licensing income (D

Royalty and licensing income (Details) - USD ($) $ in Millions	6 Months Ended
	Jan. 31, 2016	Jan. 31, 2015
Royalty and licensing income (Details) [Line Items]
Patent Expiration Date	Apr. 24, 2018
Life Sciences [Member]
Royalty and licensing income (Details) [Line Items]
Royalty Revenue	$ 0.9	$ 1.6

Segment reporting (Details)

Segment reporting (Details)	6 Months Ended
	Jan. 31, 2016
Segment Reporting [Abstract]
Number of Reportable Segments	3

Segment reporting (Details) - S

Segment reporting (Details) - Schedule of segment reporting information, by segment - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2016	Jan. 31, 2015
Revenues:
Clinical laboratory services	$ 17,523	$ 14,725	$ 34,613	$ 30,547
Product revenues	6,578	7,723	14,265	15,725
Royalty and license fee income	459	644	859	1,644
Total revenues	24,560	23,092	49,737	47,916
Operating expenses:
Cost of clinical laboratory services	10,535	9,246	20,867	19,376
Cost of product revenues	3,206	3,818	6,817	7,513
Research and development	861	834	1,728	1,625
Selling, general and administrative	11,280	9,670	21,505	19,955
Provision for uncollectible accounts receivable	459	601	1,163	1,142
Legal fee expense	2,411	2,804	4,012	5,270
Legal settlements, net	(11,650)		(18,450)
Operating income (loss)	7,458	(3,881)	12,095	(6,965)
Other income (expense)
Other	11	(17)	65	2
Foreign exchange gain (loss)	(388)	(259)	(518)	(731)
Share-based compensation included in above:
Share-based compensation	110	105	221	203
Clinical Labs [Member]
Revenues:
Clinical laboratory services	17,523	14,725	34,613	30,547
Total revenues	17,523	14,725	34,613	30,547
Operating expenses:
Cost of clinical laboratory services	10,535	9,246	20,867	19,376
Selling, general and administrative	5,649	5,089	10,935	10,157
Provision for uncollectible accounts receivable	467	658	1,175	1,189
Legal fee expense	57	41	66	131
Legal settlements, net	1,500		1,500
Total operating expenses	18,208	15,034	34,543	30,853
Operating income (loss)	(685)	(309)	70	(306)
Other income (expense)
Interest	(23)	(12)	(42)	(39)
Other	(1)	4	3	6
Income (loss) before income taxes	(709)	(317)	31	(339)
Depreciation and amortization included above	411	357	808	714
Share-based compensation included in above:
Share-based compensation	2	2	3	3
Capital expenditures	354	338	791	589
Life Sciences [Member]
Revenues:
Product revenues	6,578	7,723	14,265	15,725
Royalty and license fee income	459	644	859	1,644
Total revenues	7,037	8,367	15,124	17,369
Operating expenses:
Cost of product revenues	3,206	3,818	6,817	7,513
Research and development	661	635	1,328	1,183
Selling, general and administrative	2,773	2,704	5,832	5,853
Provision for uncollectible accounts receivable	(8)	(57)	(12)	(47)
Legal fee expense	5	(53)	(17)	(51)
Legal settlements, net	(13,150)		(19,950)
Total operating expenses	(6,513)	7,047	(6,002)	14,451
Operating income (loss)	13,550	1,320	21,126	2,918
Other income (expense)
Interest	17	5	31	7
Other		(29)	39	(35)
Foreign exchange gain (loss)	(388)	(259)	(518)	(731)
Income (loss) before income taxes	13,179	1,037	20,678	2,159
Depreciation and amortization included above	524	555	1,054	1,113
Share-based compensation included in above:
Capital expenditures	84	51	152	64
Therapeutics [Member]
Operating expenses:
Research and development	200	199	400	442
Total operating expenses	200	199	400	442
Operating income (loss)	(200)	(199)	(400)	(442)
Other income (expense)
Income (loss) before income taxes	(200)	(199)	(400)	(442)
Depreciation and amortization included above		1		2
Other Segments [Member]
Operating expenses:
Selling, general and administrative	2,858	1,877	4,738	3,945
Legal fee expense	2,349	2,816	3,963	5,190
Total operating expenses	5,207	4,693	8,701	9,135
Operating income (loss)	(5,207)	(4,693)	(8,701)	(9,135)
Other income (expense)
Interest	(36)	(42)	(71)	(86)
Other	12	8	23	31
Income (loss) before income taxes	(5,231)	(4,727)	(8,749)	(9,190)
Depreciation and amortization included above	17	22	40	44
Consolidated [Member]
Revenues:
Clinical laboratory services	17,523	14,725	34,613	30,547
Product revenues	6,578	7,723	14,265	15,725
Royalty and license fee income	459	644	859	1,644
Total revenues	24,560	23,092	49,737	47,916
Operating expenses:
Cost of clinical laboratory services	10,535	9,246	20,867	19,376
Cost of product revenues	3,206	3,818	6,817	7,513
Research and development	861	834	1,728	1,625
Selling, general and administrative	11,280	9,670	21,505	19,955
Provision for uncollectible accounts receivable	459	601	1,163	1,142
Legal fee expense	2,411	2,804	4,012	5,270
Legal settlements, net	(11,650)		(18,450)
Total operating expenses	17,102	26,973	37,642	54,881
Operating income (loss)	7,458	(3,881)	12,095	(6,965)
Other income (expense)
Interest	(42)	(49)	(82)	(118)
Other	11	(17)	65	2
Foreign exchange gain (loss)	(388)	(259)	(518)	(731)
Income (loss) before income taxes	7,039	(4,206)	11,560	(7,812)
Depreciation and amortization included above	952	935	1,902	1,873
Share-based compensation included in above:
Share-based compensation	2	2	3	3
Capital expenditures	438	389	943	653
Research and Development Expense [Member]
Share-based compensation included in above:
Share-based compensation		1		2
Research and Development Expense [Member] | Life Sciences [Member]
Share-based compensation included in above:
Share-based compensation		1		2
Research and Development Expense [Member] | Consolidated [Member]
Share-based compensation included in above:
Share-based compensation		1		2
Selling, General and Administrative Expenses [Member]
Share-based compensation included in above:
Share-based compensation	108	102	218	198
Selling, General and Administrative Expenses [Member] | Clinical Labs [Member]
Share-based compensation included in above:
Share-based compensation	9	12	19	21
Selling, General and Administrative Expenses [Member] | Life Sciences [Member]
Share-based compensation included in above:
Share-based compensation	5	3	10	3
Selling, General and Administrative Expenses [Member] | Other Segments [Member]
Share-based compensation included in above:
Share-based compensation	94	87	189	174
Selling, General and Administrative Expenses [Member] | Consolidated [Member]
Share-based compensation included in above:
Share-based compensation	108	102	218	198
Total [Member] | Clinical Labs [Member]
Share-based compensation included in above:
Share-based compensation	11	14	22	24
Total [Member] | Life Sciences [Member]
Share-based compensation included in above:
Share-based compensation	5	4	10	5
Total [Member] | Other Segments [Member]
Share-based compensation included in above:
Share-based compensation	94	87	189	174
Total [Member] | Consolidated [Member]
Share-based compensation included in above:
Share-based compensation	$ 110	$ 105	$ 221	$ 203

Contingencies (Details)

Contingencies (Details)	Jan. 04, 2016USD ($)	Oct. 31, 2015USD ($)	Jul. 31, 2015USD ($)	Apr. 22, 2014USD ($)	Nov. 30, 2012	Jun. 30, 2004	Oct. 31, 2015	Apr. 30, 2014USD ($)	Jan. 31, 2016USD ($)	Jul. 31, 2014	Jun. 20, 2014USD ($)
Contingencies (Details) [Line Items]
Gain Contingency, Patents Allegedly Infringed upon, Number						6
Number of Licensee Patents									4
Gain Contingency, Patents Found Not Infringed upon, Number					1
Gain Contingencies Prejudgement Interest									$ 12,500,000
Additional Escrow Deposit											$ 30
Amount received from escrow									7,030,000
Affymetrix Inc [Member]
Contingencies (Details) [Line Items]
Payments for Legal Settlements		$ 6,800,000
Perkin Elmer [Member]
Contingencies (Details) [Line Items]
Escrow Deposit											$ 7,000,000
Subpoena [Member]
Contingencies (Details) [Line Items]
Estimated Litigation Liability, Current									10,000,000
Additional amount accrued for achievement of milestone									1,500,000
Total liability for settlement agreement									2,700,000
Current liability for settlement agreement									1,900,000
Other liability for settlement agreement									$ 800,000
Luminex [Member]
Contingencies (Details) [Line Items]
Litigation Settlement, Amount			$ 7,100,000
Siemens [Member]
Contingencies (Details) [Line Items]
Litigation Settlement, Amount			6,700,000
Royalty Revenue			$ 1,000,000
Agilent Technologies, Inc Member
Contingencies (Details) [Line Items]
Payments for Legal Settlements	$ 6,100,000
Agreement [Member] | Affymetrix Inc [Member]
Contingencies (Details) [Line Items]
Litigation Settlement, Amount				$ 5,100,000
Proceeds from Legal Settlements				4,300,000
Litigation Settlement, Expense				$ 800,000
Subpoena [Member]
Contingencies (Details) [Line Items]
Investigation Period									The time period initially covered by the investigation was from 2004 through 2011
Estimated Litigation Settlement Amount								$ 2,000,000
Period Over Which Settlement Amount Has to Be Paid								5 years
Additional Payment of Litigation Settlement Amount									$ 1,500,000
Percentage of Additional Payment of Litigation Settlement Amount over Additional Capital Receipt									20.00%
Indemnification Agreement [Member]
Contingencies (Details) [Line Items]
Gain Contingency, Unrecorded Amount									$ 48,500,000
Minimum [Member] | Siemens [Member]
Contingencies (Details) [Line Items]
Litigation Settlement Period			2,015
Minimum [Member] | Subpoena [Member]
Contingencies (Details) [Line Items]
Litigation Settlement Period									2,004	2,004
Amount of Additional Capital Receipt Condition for Litigation Settlement									$ 10,000,000
Maximum [Member] | Siemens [Member]
Contingencies (Details) [Line Items]
Litigation Settlement Period			2,019
Maximum [Member] | Subpoena [Member]
Contingencies (Details) [Line Items]
Litigation Settlement Period							2,014